Zydus Lifesciences Unit Partners With Prolific Machines For Biologics Manufacturing

The partnership aims to scale Prolific's optogenetics technology from laboratory to GMP production. Zylidac Bio will integrate Prolific’s illumination hardware into its existing bioreactors at its Emeryville facility.

Reader Takeaway: Zydus gains advanced tech to boost biologics yield; operational risks include successful tech transfer at scale.

What just happened

Zylidac Bio, a subsidiary of Zydus Lifesciences, has entered into a strategic collaboration with Prolific Machines. The agreement focuses on scaling Prolific’s optogenetics-enabled cell line development platform, which uses light to control protein expression, potentially improving yields and quality for complex biologics like multi-specific antibodies and cytokines.

Why this matters

This partnership provides Zydus a competitive edge in the Contract Development and Manufacturing Organization (CDMO) space. By integrating Prolific’s hardware into its existing infrastructure, Zylidac can offer clients a seamless transition from early-stage development to full GMP manufacturing without requiring significant new infrastructure investment from the client.

What changes now

Both companies, based in Emeryville, California, will begin a technology transfer at a 50-liter scale at the Zylidac site. Success in this phase will trigger a scale-up to 250 liters and eventually to full-scale commercial GMP production, encompassing drug substance manufacturing, fill-finish, and packaging.

What to track next

Investors should watch for updates on the successful completion of the initial 50-liter tech transfer and subsequent client adoption rates for this integrated service offering. The ability to demonstrate consistent process control and improved yield at scale will be critical for the unit's long-term commercial performance.